Nevirapine Plasma Concentrations Are Associated with Virologic Response and Hepatotoxicity in Chinese Patients with HIV Infection
Open Access
- 31 October 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (10) , e26739
Abstract
Limited information is available on the relationship between nevirapine plasma concentrations and virologic response or liver toxicity in Chinese patients with HIV infection. The objective of this prospective study was to test this relationship and to determine the minimal therapeutic trough concentration of nevirapine for Chinese patients. A total of 227 HIV-infected, treatment naïve patients were enrolled into this study. Blood samples were taken at Ctrough (12 hr postdose) and C2 (2 hr postdose) for measurement of nevirapine concentrations 6 months after treatment initiation. Therapeutic outcomes, viral load and CD4 cell count, were assessed at 3 and 6 months after starting therapy, while the evaluation of hepatotoxicity was undertaken 12 months after nevirapine treatment. A significant correlation between nevirapine trough concentrations and viral load was noticed after 6 months of treatment, particularly in patients with partial response and viral failure (ptrough of nevirapine for Chinese patients was determined to be 3.9 µg/ml using the receiver operating characteristic curve. Virologic failure was observed in 21% (6/29) of patients with low nevirapine concentrations (vs. 5.48 µg/ml, p = 0.015) and hepatitis C virus co-infection (p = 0.039). Among Chinese patients with HIV infection, the therapeutic Ctrough of nevirapine was 3.9 µg/ml, higher than the recommended 3.0 µg/ml. The correlation between nevirapine concentrations, efficacy and hepatotoxicity suggests the benefit of dosage adjustment based on therapeutic drug monitoring among Chinese HIV-infected patients to optimize nevirapine containing antiretroviral therapy.Keywords
This publication has 23 references indexed in Scilit:
- Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese HIV/AIDS Patients: Multicentric Observation CohortPLOS ONE, 2008
- Variability in non‐nucleoside reverse transcriptase and protease inhibitors concentrations among HIV‐infected adults in routine clinical practiceBritish Journal of Clinical Pharmacology, 2007
- Are Adverse Events of Nevirapine and Efavirenz Related to Plasma Concentrations?Antiviral Therapy, 2005
- Pharmacogenomics and HIV TherapeuticsThe Journal of Infectious Diseases, 2005
- Low Trough Plasma Concentrations of Nevirapine Associated with Virologic Rebounds in HIV-Infected Patients Who Switched from Protease InhibitorsAnnals of Pharmacotherapy, 2005
- No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitorsEuropean Journal of Clinical Pharmacology, 2004
- Short Communication : Interactions between Nevirapine Plasma Levels, Chronic Hepatitis C, and the Development of Liver Toxicity in HIV-Infected PatientsAIDS Research and Human Retroviruses, 2003
- Low Nevirapine Plasma Concentrations Predict Virological Failure in an Unselected HIV-1-Infected PopulationClinical Pharmacokinetics, 2003
- Liver toxicity caused by nevirapineAIDS, 2002
- High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individualsAIDS, 2001